AMGEN Inc.
AMGN
Market Cap$140.93B
Close$
Earnings Call Q4 2023
February 6, 2024 - AI Summary
Amgen reported strong performance in 2023, with double-digit volume growth in all four quarters and record sales for 18 of its medicines.
The acquisition of Horizon Therapeutics has added a significant rare disease business to Amgen's portfolio, positioning it for long-term growth.
Promising pipeline milestones are expected in 2024, including Phase II data for the lead obesity molecule MariTide and Phase III data for several other assets.
Exclusive for Stockcircle Pro members
Sign up
$473.58
73.1% upside
Current Fair Value
73.1% upsideUndervalued by 73.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $140.93 Billion |
|---|---|
| Enterprise Value | $194.60 Billion |
| Dividend Yield | $8.4595 (3.22%) |
| Earnings per Share | $12.49 |
| Beta | 0.6 |
| Outstanding Shares | 536,375,548 |
| Avg 30 Day Volume | 2,162,343 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 20.98 |
|---|---|
| PEG | -39.94 |
| Price to Sales | 5.26 |
| Price to Book Ratio | 24.87 |
| Enterprise Value to Revenue | 6.9 |
| Enterprise Value to EBIT | 24.64 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | 10.37 |
Revenue Sources
No data
ESG Score
No data
About AMGEN Inc.
22,000 employees
CEO: Robert Bradway Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advan...